MGWM
CYTK icon

Marks Group Wealth Management’s Cytokinetics CYTK Stock Holding History

Marks Group Wealth Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.54M Buy
18,024
+1,189
+7% +$85.4K 0.13% 165
2026
Q1 		$1.11M Buy
16,835
+2,269
+16% +$144K 0.11% 186
2025
Q4 		$926K Buy
+14,566
New +$906K 0.09% 195

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marks Group Wealth Management's CYTK Position: Q2 2026 in Review

Marks Group Wealth Management increased its Cytokinetics (CYTK) stake by 7.1% in Q2 2026, buying an estimated $85.4K and bringing the position to 18,024 shares worth $1.54M. The position accounts for 0.13% of the portfolio, ranked #165.

Marks Group Wealth Management first reported a position in CYTK in Q4 2025 and has held it in 3 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Marks Group Wealth Management held 18,024 shares of Cytokinetics worth $1.54M as of Q2 2026.
  • Marks Group Wealth Management bought 1,189 Cytokinetics shares in Q2 2026, an estimated $85.4K.
  • Cytokinetics made up 0.13% of Marks Group Wealth Management's portfolio in Q2 2026, its #165 holding.
  • Marks Group Wealth Management first reported a position in Cytokinetics in Q4 2025 and has held it in 3 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Marks Group Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.